Bioheart Launches First US FDA Approved Clinical Trial That Tests Gene-Modified Stem Cell Therapy In Patients With Congestive Heart Failure
Bioheart, Inc., (OTCBB:BHRT) announced that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials…
Related News:
Bioheart Launches First US FDA Approved Clinical Trial That Tests Gene-Modified Stem Cell Therapy In Patients With …
Bioheart Commenced Successful Regenerative Stem Cell Treatments With Latin American Patients Having Congestive Heart Failure
Bioheart Commenced Successful Regenerative Stem Cell Treatments with Latin American Patients Having Congestive Heart …